Trial Profile
A multicenter, randomized, parallel controlled, exploratory clinical trial for antlotinib hydrochloride plus docetaxel plus cisplatin versus docetaxel plus cisplatin in the treatment of T790M negative-mutation non-small cell lung cancer with EGFR-TKI failure
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2018 New trial record